



**Virtual event**

Technology and process advancements  
in cell and gene therapy development.

| Date   | Time             | Track | Presentation Title   | Speaker   |
|--------|------------------|-------|--|---|
| 20-Mar | 10:00 - 10:30 AM |       | Semi-automated, closed processing of mesenchymal stromal cells   | Dr. Alan Lam, PhD<br>Senior Scientist, Bioprocessing Technology Institute A*STAR<br>Dr. Qu Yinghua, PhD<br>Field Application Scientist, Cell & Gene Therapy, SEATW Thermo Fisher Scientific   |
| 20-Mar | 10:35 - 11:15 AM |       | Advancing process efficiency for the end-to-end manufacturing of T cell immunotherapies  | Dr. Paula Lam, PhD<br>Chief Scientific Officer, BioCell Innovations, Singapore<br>Dr. Sylvie Shen, PhD<br>Field Application Scientist, Cell & Gene Therapy, Australasia Thermo Fisher Scientific  |
| 20-Mar | 11:20 - 11:45 AM |       | The experience of development and verification of analytical platforms for cellular and gene therapy (CGT) products in EMO Biomedicine | Shing-Mou Lee<br>CEO & Lab Head, EMO Biomedicine Corp.  |
| 20-Mar | 11:50 - 12:15 PM |       | Safety first: A comprehensive look at cell and gene therapy testing  | Karolina Setyowati, Ph.D.<br>Sr Product Specialist, APJ, Thermo Fisher Scientific   |
| 20-Mar | 12:20 - 12:40 PM |       | Regulatory considerations in raw material selection for cell and gene therapy manufacturing  | Bingrong Chen<br>Manager, Regulatory Affairs Thermo Fisher Scientific   |
| 20-Mar | 12:45 - 01:15 PM |       | Panel discussion   | Dr. Sylvie Shen, PhD<br>Field Application Scientist, Cell & Gene Therapy, Australasia Thermo Fisher Scientific<br>Shing-Mou Lee<br>CEO & Lab Head, EMO Biomedicine Corp.<br>Bingrong Chen<br>Manager, Regulatory Affairs Thermo Fisher Scientific |